Source:http://linkedlifedata.com/resource/pubmed/id/10442198
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
1999-10-8
|
| pubmed:abstractText |
Although the potential activity of anticancer agents has been traditionally assessed by the response rate (RR) in phase II trials, there is an increasing need to identify alternative endpoints to evaluate the efficacy of novel types of antineoplastic agents such as cytostatic agents. However, none of the proposed alternatives have been validated.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0923-7534
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
10
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
731-3
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:10442198-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:10442198-Clinical Trials, Phase II as Topic,
pubmed-meshheading:10442198-Disease Progression,
pubmed-meshheading:10442198-Humans,
pubmed-meshheading:10442198-Lung Neoplasms,
pubmed-meshheading:10442198-Outcome Assessment (Health Care),
pubmed-meshheading:10442198-Research Design,
pubmed-meshheading:10442198-Survival Analysis,
pubmed-meshheading:10442198-Treatment Outcome
|
| pubmed:year |
1999
|
| pubmed:articleTitle |
Progressive disease rate as a surrogate endpoint of phase II trials for non-small-cell lung cancer.
|
| pubmed:affiliation |
Internal Medicine & Thoracic Oncology Division, National Cancer Center Hospital, Tokyo, Japan. isekine@gan2.ncc.go.jp
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|